Chris Murphy is the Chief Executive Officer of ElevateBio and a member of its Board of Directors. Chris brings more than 35 years of leadership, operational, and commercial experience across biopharmaceutical and manufacturing sectors.
by
Bhakti has more than 20 years of experience in biotech, consulting, and financial services including corporate finance, business development, strategy, and business process re-engineering. Bhakti joined ElevateBio as one of earliest employees and has been leading the finance team since 2018.
Steve Falcone is the Chief Operating Officer at ElevateBio. Steve brings more than 30 years of operations, quality, and compliance leadership across global biopharmaceutical manufacturing.
Catherine Hu joined ElevateBio in 2021 to lead the Company’s corporate affairs and investor relations functions. Prior to ElevateBio, Catherine led investor relations, corporate affairs, and patient advocacy functions at Scholar Rock, Inc. and was part of the investor relations team at Alexion Pharmaceuticals.
Katie Jorgensen joined ElevateBio in 2021 and as Site Head at BaseCamp Waltham, she is responsible for supply chain, facilities, technical operations, manufacturing, and program management supporting strategic contracts and valued partnerships bringing innovative cell and gene therapies to patients. Previously, she was the Company’s VP, Commercial Operations and CMC Program Management.
Missy has more than 15 years of experience in operations and people strategies. As a strategic thought partner to the leadership team, she identifies areas for operational improvement, provides insight and analysis on company strategy and operations, and ensures a continued focus on top priorities across the company.
Larry has more than 20 years of leadership experience and deep technical expertise, with proven success in building and scaling commercial teams, driving revenue growth, and establishing global partnerships. Currently, Larry is the Chief Commercial Officer at ElevateBio where he leads commercial strategy to accelerate revenue growth by expanding partnerships across ElevateBio.
Michael has spent the last twenty years in biotechnology building, leading and motivating process development and manufacturing teams to support clinical programs from early development to late-stage clinical trials. Currently, Michael is the Chief Technology Officer at ElevateBio and is responsible for it’s technology offerings, including cell therapy, LentiPeakTM platform, and process development.
Katherine has over 20 years of experience in biomanufacturing operations including multiple new facility startups. She currently serves as Site Head, BaseCamp Pittsburgh and is responsible for supply chain, facilities, technical operations, manufacturing, and program management.
David Hallal is a 30-year veteran in the biopharmaceutical industry with expertise in early-stage company building as well as operating large multinational biotech companies. He is a co-founder of ElevateBio, previously served as Chairman and CEO, and now serves as Executive Chairman on its Board of Directors. He is currently CEO of Scholar Rock.
Vikas Sinha brings more than 30 years of experience in executive finance roles in the life sciences industry. He is a co-founder of ElevateBio, previously served as CFO, and now serves as on its Board of Directors and is Chair of the Audit Comittee. He is Chief Financial Officer of Scholar Rock.
Ben Kleinstiver is an Associate Professor at Massachusetts General Hospital and Harvard Medical School. His laboratory is focused on developing and applying protein engineering methods to improve genome editing technologies. He received his Ph.D in Biochemistry from the University of Western Ontario, and completed his postdoctoral studies at MGH and HMS. The major goals of the research in his laboratory are to address limitations of existing technologies, to develop new capabilities that will help solve important research questions in the genome editing field, all with the hope of providing safe and effective treatments for patients.
